Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2Is)

Core Concepts

The kidney's glucose economy

Every day the kidneys filter a large amount of glucose; in a healthy person essentially all of it is reabsorbed, so urine contains no sugar. Reabsorption happens mainly in the proximal convoluted tubule (PCT), the nephron's first segment, through two transporters:

• SGLT2 — high capacity, does most of the work (roughly 90% of filtered glucose in typical teaching models), in the early PCT.
• SGLT1 — lower capacity, picks up the remainder further along.

Blocking SGLT2 leaves glucose in the tubule to exit in urine (glucosuria). How much glucose is lost depends on how much is filtered — so the effect is largest when blood glucose is high. In people without diabetes, urine glucose loss is smaller and the sodium/fluid effects become relatively more important.

Sodium and fluid effects: the hemodynamic story

Blocking SGLT2 also leaves sodium in the tubule. Some is reabsorbed further down, but a net amount is excreted, pulling water with it (osmotic diuresis) — a modest, sustained reduction in plasma volume that gently "unloads" the heart:

• Less preload — less volume returning to stretch a failing ventricle.
• Less afterload — some blood-pressure and vascular-tone effect.
• Reduced intraglomerular pressure — via tubuloglomerular feedback, lowering the workload on the kidney's filters, which is why the drugs also protect kidney function over time.

These hemodynamic effects are proposed as a major reason for the heart failure benefit — a mild, continuous diuresis-like effect without the large electrolyte swings of classic diuretics. The renal mechanism is well established; the cardiac benefit likely involves several pathways, some still under investigation — flag for source/SME review rather than asserting as settled.

Other proposed cardiac mechanisms (still being studied)

Beyond volume reduction, researchers propose that SGLT2 inhibitors shift myocardial fuel use (more ketones and fatty acids), reduce inflammation and fibrosis, improve cardiac energetics, and alter sodium handling in heart muscle. These hypotheses explain parts of the benefit volume alone cannot and remain active research areas. For exam purposes: the drugs reduce hospitalizations and cardiovascular death in heart failure; the full mechanism is multifactorial and not completely settled.

Use in heart failure — with or without diabetes

The key clinical point: SGLT2 inhibitors are recommended in heart failure regardless of diabetes status. They are oral and generally well tolerated, used across the ejection fraction spectrum per current guidelines — verify the precise recommendations for HFrEF, HFmrEF, and HFpEF against the latest references and formulary.

Class-level adverse effects and monitoring

Each adverse effect follows from the mechanism:

• Genital mycotic (fungal) infections — glucosuria feeds yeast, so genital candidiasis is more common, especially with diabetes. Teach hygiene and to report itching, discharge, or irritation. (UTIs are also reported; monitor per orders.)
• Volume depletion and hypotension — the natriuresis can be excessive with loop diuretics, hot weather, or illness. Monitor weight, blood pressure, and dizziness; per orders, diuretic doses may need adjustment — never independently.
• Kidney function changes — a small eGFR dip shortly after starting is an expected hemodynamic effect that usually stabilizes; ongoing or severe decline warrants prescriber review.
• Euglycemic DKA — in people with diabetes, SGLT2 inhibitors carry a DKA risk even when blood glucose is only mildly elevated or "normal." Teach sick-day rules: stay hydrated, do not stop diabetes medications without prescriber direction, seek care for nausea, vomiting, abdominal pain, or unusual fatigue. The classic glucose-based warning signs are unreliable here.
• Other signals — some agents have carried labeling about lower-limb amputation or bone fracture risks; labeling differs between agents and evolves. Verify current product labeling rather than generalizing across the class.

Nursing implications

Before and during therapy: verify the indication and orders, review baseline kidney function and volume status, and assess for dizziness or orthostatic hypotension. Teach what to expect (more frequent urination, possible weight change) and what to report (dizziness, genital symptoms, illness with poor intake, dehydration signs). Many people will say "this is my diabetes pill" — explain it is prescribed for the heart's benefit even when blood sugar is normal.

Common Confusions